Published in Schizophr Bull on March 15, 2006
Switching Antipsychotics: Abrupt Discontinuation Versus Overlap | NCT02640300
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull (2009) 4.69
Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2010) 2.13
Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull (2008) 1.93
Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry (2010) 1.65
Antipsychotic medication for early episode schizophrenia. Cochrane Database Syst Rev (2011) 1.49
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry (2010) 1.49
Do effectiveness ("real world") studies on antipsychotics tell us the real truth? Eur Arch Psychiatry Clin Neurosci (2008) 1.47
Intent-to-Treat vs. Non-Intent-to-Treat Analyses under Treatment Non-Adherence in Mental Health Randomized Trials. Psychiatr Ann (2008) 1.36
The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology (2007) 1.31
Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res (2008) 1.23
When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res (2011) 1.15
Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci (2010) 1.02
Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life. Ther Adv Psychopharmacol (2016) 0.97
Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials. BMC Psychiatry (2014) 0.97
The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophr Bull (2015) 0.96
Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology (2011) 0.95
Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. Acta Neuropsychiatr (2011) 0.93
Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry (2014) 0.93
Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull (2011) 0.91
Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacology (Berl) (2009) 0.91
Unanswered questions in schizophrenia clinical trials. Schizophr Bull (2008) 0.90
Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatr Dis Treat (2011) 0.89
Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample. J Korean Med Sci (2014) 0.87
Schizophrenia--time to commit to policy change. Schizophr Bull (2014) 0.86
Current perspectives in the treatment of resistant schizophrenia. Indian J Psychiatry (2010) 0.86
Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull (2008) 0.85
Antipsychotic polypharmacy in a regional health service: a population-based study. BMC Psychiatry (2012) 0.84
Improvement and decline of cognitive function in schizophrenia over one year: a longitudinal investigation using latent growth modelling. BMC Psychiatry (2007) 0.84
Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid program. Community Ment Health J (2010) 0.83
Recent advances in understanding schizophrenia. F1000Prime Rep (2014) 0.83
Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology (2010) 0.83
Left Ventricular Thrombus as a Complication of Clozapine-Induced Cardiomyopathy: A Case Report and Brief Literature Review. Case Rep Cardiol (2015) 0.83
Factors associated with response to clozapine in schizophrenia: a review. Psychopharmacol Bull (2011) 0.82
Validity of subjective versus objective quality of life assessment in people with schizophrenia. BMC Psychiatry (2014) 0.82
Clozapine: Current perspective. Indian J Psychiatry (2007) 0.82
Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia? Neurotherapeutics (2009) 0.82
Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data. Schizophr Res (2014) 0.81
Second generation antipsychotics improve sexual dysfunction in schizophrenia: a randomised controlled trial. Schizophr Res Treatment (2011) 0.81
Continuing clozapine with granulocyte colony-stimulating factor in patients with neutropenia. Ther Adv Psychopharmacol (2013) 0.79
Validation of the Chinese version of the Clinical Assessment Interview for Negative Symptoms (CAINS): a preliminary report. Front Psychol (2015) 0.79
Clozapine improves symptoms but not quality of life compared with other second-generation antipsychotics in people with treatment resistant schizophrenia. Evid Based Ment Health (2007) 0.79
Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacology (Berl) (2009) 0.79
Clozapine prescribing in the UK: views and experience of consultant psychiatrists. Ther Adv Psychopharmacol (2015) 0.78
Randomized controlled trials for schizophrenia: study designs targeted to distinct goals. Schizophr Bull (2008) 0.78
Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms. Can J Psychiatry (2015) 0.78
Association Between Antipsychotic Treatment and Advanced Diabetes Complications Among Schizophrenia Patients With Type 2 Diabetes Mellitus. Schizophr Bull (2015) 0.78
Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham-controlled, randomized multicenter study. Eur Arch Psychiatry Clin Neurosci (2009) 0.77
Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMDA receptor-mediated transmission. Neuropsychopharmacology (2010) 0.77
Coverage of atypical antipsychotics among medicare drug plans in the state of washington for fiscal year 2007. Prim Care Companion J Clin Psychiatry (2008) 0.77
First- and second-generation antipsychotic drug treatment and subcortical brain morphology in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2015) 0.76
The ANNSERS (Antipsychotic Non-Neurological Side Effects Rating Scale): Validation of Sexual Side-Effect Measurement. Ther Adv Psychopharmacol (2011) 0.76
Continuing clozapine treatment with lithium in schizophrenic patients with neutropenia or leukopenia: brief review of literature with case reports. Ther Adv Psychopharmacol (2016) 0.75
What Is the Place of Clozapine in the Treatment of Early Psychosis in Canada? Can J Psychiatry (2016) 0.75
A Case of Clozapine-Induced Myocarditis in a Young Patient with Bipolar Disorder. Case Rep Cardiol (2015) 0.75
Quo Vadis Clozapine? A Bibliometric Study of 45 Years of Research in International Context. Int J Mol Sci (2015) 0.75
Burning pain secondary to clozapine use: a case report. BMC Psychiatry (2014) 0.75
A therapeutic interaction between cimetidine and clozapine: case study and review of the literature. Ther Adv Psychopharmacol (2013) 0.75
Towards a framework for treatment effectiveness in schizophrenia. Neuropsychiatr Dis Treat (2014) 0.75
Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability. Ther Adv Psychopharmacol (2016) 0.75
Effectiveness of antipsychotics used in first-episode psychosis: a naturalistic cohort study. BJPsych Open (2016) 0.75
Prescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a cross-sectional survey of early intervention teams. Ther Adv Psychopharmacol (2016) 0.75
Significant weight loss following clozapine use, how is it possible? A case report and review of published cases and literature relevant to the subject. Ther Adv Psychopharmacol (2016) 0.75
Curious cases--The curious case of a man with schizophrenia and excessive aggression. Schizophr Bull (2012) 0.75
Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review. Neurol Ther (2016) 0.75
Clozapine-induced, dilated cardiomyopathy: a case report. BMC Res Notes (2017) 0.75
Blood Pressure and Heart Rate Changes During Clozapine Treatment. Psychiatr Q (2016) 0.75
Clozapine as a Model for Antipsychotic Development. Neurotherapeutics (2017) 0.75
[Pharmacotherapy for schizophrenia]. Nervenarzt (2006) 0.75
The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 51.07
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry (1988) 12.39
A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl (1970) 10.05
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry (2006) 9.44
The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull (1984) 5.69
The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl (1987) 4.49
A depression rating scale for schizophrenics. Schizophr Res (1991) 3.70
A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med (1983) 3.46
A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med (1997) 3.12
Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods. Stat Methods Med Res (2005) 2.59
Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry (2001) 2.35
Estimating psychological treatment effects from a randomised controlled trial with both non-compliance and loss to follow-up. Br J Psychiatry (2003) 2.19
Likelihood methods for treatment noncompliance and subsequent nonresponse in randomized trials. Biometrics (2005) 1.91
Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry (2001) 1.88
Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol (2004) 1.61
Measures of quality of life among persons with severe and persistent mental disorders. Soc Psychiatry Psychiatr Epidemiol (1996) 1.56
Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry (1994) 1.44
Evaluation of treatment-resistant schizophrenia. Schizophr Bull (1997) 1.31
A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess (2003) 1.11
Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull (1996) 1.08
Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry (2002) 1.04
Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry (1996) 1.04
Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry (1995) 1.01
Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev (2000) 1.01
Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst Rev (2000) 1.00
Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Prog Neuropsychopharmacol Biol Psychiatry (2000) 0.88
Covariate adjustment in clinical trials with non-ignorable missing data and non-compliance. Stat Med (2004) 0.82
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet (2007) 11.27
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry (2006) 9.44
Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet (2013) 7.44
Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation (2002) 6.22
Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry (2004) 5.95
The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ (2004) 4.92
Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet (2003) 4.84
Cognitive--behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomised controlled trial. Br J Psychiatry (2008) 4.14
Epigenome-wide scans identify differentially methylated regions for age and age-related phenotypes in a healthy ageing population. PLoS Genet (2012) 4.05
Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry (2002) 4.03
Effectiveness of enhanced communication therapy in the first four months after stroke for aphasia and dysarthria: a randomised controlled trial. BMJ (2012) 4.01
A twin study of genetic relationships between psychotic symptoms. Am J Psychiatry (2002) 3.95
Why psychiatry can't afford to be neurophobic. Br J Psychiatry (2009) 3.80
Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry (2009) 3.67
Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry (2002) 3.59
Virtual reality study of paranoid thinking in the general population. Br J Psychiatry (2008) 3.40
Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. Arch Gen Psychiatry (2006) 3.35
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry (2003) 3.18
Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psychiatry (2010) 3.05
Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet (2011) 2.99
Mental health of Kosovan Albanian refugees in the UK. Br J Psychiatry (2003) 2.80
Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC AESOP Study. Psychol Med (2006) 2.79
Symmetries in human brain language pathways correlate with verbal recall. Proc Natl Acad Sci U S A (2007) 2.78
Nurse led, home based self help treatment for patients in primary care with chronic fatigue syndrome: randomised controlled trial. BMJ (2010) 2.74
Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ (2012) 2.70
The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. J Clin Psychiatry (2015) 2.67
Cognitive-behavioural therapy in first-episode and early schizophrenia. 18-month follow-up of a randomised controlled trial. Br J Psychiatry (2004) 2.54
Outcomes of conduct problems in adolescence: 40 year follow-up of national cohort. BMJ (2009) 2.47
Prevalence and correlates of self-reported psychotic symptoms in the British population. Br J Psychiatry (2004) 2.44
Mediation and moderation of treatment effects in randomised controlled trials of complex interventions. Stat Methods Med Res (2009) 2.43
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry (2012) 2.41
High-potency cannabis and the risk of psychosis. Br J Psychiatry (2009) 2.41
Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry (2011) 2.37
Early treatment for Class II Division 1 malocclusion with the Twin-block appliance: a multi-center, randomized, controlled trial. Am J Orthod Dentofacial Orthop (2009) 2.34
Disease-relevant autoantibodies in first episode schizophrenia. J Neurol (2010) 2.33
Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses. PLoS One (2012) 2.33
Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res (2004) 2.30
Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction (2007) 2.20
Psychotic experiences and psychotic disorders at age 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort study. Am J Psychiatry (2013) 2.17
Group art therapy as an adjunctive treatment for people with schizophrenia: multicentre pragmatic randomised trial. BMJ (2012) 2.17
Schizophrenia in the offspring of antenatally depressed mothers in the northern Finland 1966 birth cohort: relationship to family history of psychosis. Am J Psychiatry (2009) 2.11
Cluster randomised controlled trial of training practices in reattribution for medically unexplained symptoms. Br J Psychiatry (2007) 2.10
A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophrenia. Schizophr Res (2011) 2.09
Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study. Br J Psychiatry (2011) 2.06
Adolescents who were born very preterm have decreased brain volumes. Brain (2002) 1.97
Raised incidence rates of all psychoses among migrant groups: findings from the East London first episode psychosis study. Arch Gen Psychiatry (2008) 1.96
Negative life events, social support and gender difference in depression: a multinational community survey with data from the ODIN study. Soc Psychiatry Psychiatr Epidemiol (2006) 1.95
Temporal course of auditory hallucinations. Br J Psychiatry (2004) 1.95
Comparing hospital and telephone follow-up after treatment for breast cancer: randomised equivalence trial. BMJ (2009) 1.95
Specialised care for early psychosis: symptoms, social functioning and patient satisfaction: randomised controlled trial. Br J Psychiatry (2006) 1.94
Reliability and comparability of psychosis patients' retrospective reports of childhood abuse. Schizophr Bull (2009) 1.94
Grey and white matter distribution in very preterm adolescents mediates neurodevelopmental outcome. Brain (2007) 1.91
Association of genetic risks for schizophrenia and bipolar disorder with specific and generic brain structural endophenotypes. Arch Gen Psychiatry (2004) 1.87
Regional volume deviations of brain structure in schizophrenia and psychotic bipolar disorder: computational morphometry study. Br J Psychiatry (2005) 1.83
Imaging macrophage chemotaxis in vivo: studies of microtubule function in zebrafish wound inflammation. Cell Motil Cytoskeleton (2006) 1.79
Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. 18-month outcomes of a randomised controlled trial. Br J Psychiatry (2003) 1.78
Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology (2005) 1.76
Deaths from natural causes in people with mental illness: a cohort study. J Psychosom Res (2008) 1.73
Self-harm in first-episode psychosis. Br J Psychiatry (2008) 1.72
A diffusion tensor imaging study of fasciculi in schizophrenia. Am J Psychiatry (2007) 1.71
Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry (2007) 1.71
Neural responses to sad facial expressions in major depression following cognitive behavioral therapy. Biol Psychiatry (2008) 1.70
Infant developmental milestones and subsequent cognitive function. Ann Neurol (2007) 1.69
Developmental typology of trajectories to nighttime bladder control: epidemiologic application of longitudinal latent class analysis. Am J Epidemiol (2003) 1.65
The Brief Core Schema Scales (BCSS): psychometric properties and associations with paranoia and grandiosity in non-clinical and psychosis samples. Psychol Med (2006) 1.64
Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry (2012) 1.64
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology (2009) 1.62
Structural magnetic resonance imaging in bipolar disorder: an international collaborative mega-analysis of individual adult patient data. Biol Psychiatry (2010) 1.60
Neurocognitive deficits in first-episode schizophrenic patients and their first-degree relatives. Am J Med Genet B Neuropsychiatr Genet (2007) 1.59
A comparison of two delivery modalities of a mobile phone-based assessment for serious mental illness: native smartphone application vs text-messaging only implementations. J Med Internet Res (2013) 1.58
The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. BMC Psychiatry (2012) 1.58
Pathways to schizophrenia: the impact of environmental factors. Int J Neuropsychopharmacol (2004) 1.58
Migration, ethnicity, and psychosis: toward a sociodevelopmental model. Schizophr Bull (2010) 1.58
Dental auxiliaries for dental care traditionally provided by dentists. Cochrane Database Syst Rev (2014) 1.56
Insight as a predictor of the outcome of first-episode nonaffective psychosis in a prospective cohort study in England. J Clin Psychiatry (2007) 1.56
Emotion and psychosis: links between depression, self-esteem, negative schematic beliefs and delusions and hallucinations. Schizophr Res (2006) 1.55
Corpus callosum size and very preterm birth: relationship to neuropsychological outcome. Brain (2004) 1.55
Childhood cognitive ability and adult mental health in the British 1946 birth cohort. Soc Sci Med (2007) 1.54
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum (2012) 1.54
Forty-year psychiatric outcomes following assessment for internalizing disorder in adolescence. Am J Psychiatry (2007) 1.54
Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry (2008) 1.53